Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.
Dr. Reddy's Laboratories Limited (RDY) is a leading multinational pharmaceutical company headquartered in Hyderabad, Telangana, India. Founded by Kallam Anji Reddy, the company has grown to become one of the largest generic drug manufacturers globally. Dr. Reddy's offers a diverse product portfolio that includes not only generic medications but also injectables and active pharmaceutical ingredients (APIs).
Dr. Reddy's has a substantial footprint in North America, which accounts for approximately 50% of its generics sales. The company also serves markets in India (22% of generics sales), Russia (12%), and various European and Latin American countries. In North America, injectables constitute 25% of its sales, showcasing the company’s ability to innovate and meet various healthcare needs.
Within branded generic markets, particularly in India, Dr. Reddy's has secured a top-five position in critical therapeutic areas such as oncology and gastroenterology. The company’s strong brand reputation has empowered it to achieve significant success in these sectors.
Furthermore, Dr. Reddy's operates a robust API business, manufacturing over 150 APIs and distributing them in more than 75 countries worldwide. This extensive network highlights the company's commitment to quality and global health.
Dr. Reddy's continues to advance its mission through ongoing projects and innovations. Recent achievements, partnerships, and financial health indicators demonstrate a stable and growing enterprise. Investors keen to stay informed about the latest developments in Dr. Reddy's Laboratories can find up-to-date news from various sources, ensuring they remain well-informed on company performance and growth trajectories.
Dr. Reddy's Laboratories and Senores Pharmaceuticals announced the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S., a generic equivalent of Toradol. This nonsteroidal anti-inflammatory drug (NSAID) is indicated for short-term management of acute pain. The U.S. market for Toradol tablets had sales of approximately $16.8 million in the past year. The product is available in bottles of 100, enhancing Dr. Reddy's portfolio in the U.S. market.
Dr. Reddy’s Laboratories has launched Posaconazole Delayed-Release Tablets, a generic equivalent to NOXAFIL®, approved by the U.S. FDA. The product is now available in 100 mg strength, with U.S. sales of NOXAFIL® reaching approximately $140.8 million over the past year. This move supports Dr. Reddy’s commitment to providing affordable, innovative medicines. The tablets come in a bottle count of 60.
Dr. Reddy’s Laboratories has launched Methylprednisolone Sodium Succinate for Injection, a generic version of SOLU-MEDROL® in the U.S., approved by the USFDA. The brand and its generic have recorded U.S. sales of approximately $144 million over the last twelve months ending February 2022, according to IQVIA Health. This product is available in both single-dose and multi-dose vials. Dr. Reddy’s focuses on providing affordable medicines and operates in major markets including the U.S., India, and Europe.
Dr. Reddy's (NYSE:RDY) has launched medical cannabis products in Germany through an exclusive distribution agreement with MediCane. This partnership, established in 2021, allows Dr. Reddy's to market MediCane's products while also co-funding a phase II clinical trial targeting Behavioral and Psychological Symptoms of Dementia (BPSD). With Germany's medical cannabis market growing, valued at ~122 million euros and expanding at a ~25% growth rate, this alliance positions Dr. Reddy's to significantly impact the European market, capitalizing on increasing patient demand.
Dr. Reddy's Laboratories Ltd. has launched its authorized generic version of VASOSTRICT® (vasopressin injection, USP) in the U.S. This release, approved by the U.S. Food and Drug Administration, responds to a significant market demand, with the VASOSTRICT® brand generating approximately $878.5 million in U.S. sales over the past twelve months ending December 2021.
The product is supplied in a carton of 25 single-dose vials, each containing vasopressin 1 mL at 20 units/mL. This launch is particularly relevant during the ongoing COVID-19 pandemic.
Dr. Reddy's Laboratories has announced its definitive agreement to acquire Nimbus Health GmbH, a licensed pharmaceutical wholesaler based in Germany, focusing on medical cannabis. This acquisition involves an upfront payment and performance-based earn-outs expected over the next four years. With a growing medical cannabis market in Germany, currently valued at ~€122 million and experiencing significant growth, this strategic move aims to leverage Nimbus Health's strengths in serving patients with unmet medical needs. The transaction is subject to customary closing conditions.
Dr. Reddy’s Laboratories Ltd. has launched Venlafaxine ER Tablets, which are therapeutically equivalent to Osmotica Pharmaceutical's product. The FDA approved these tablets in strengths of 150 mg and 225 mg, contributing to the U.S. market with sales around $51 million for the year ending October 2021. The new products come in bottle sizes of 30 and 90. The release includes important safety information regarding suicidality risks associated with antidepressants, emphasizing careful monitoring for patients.
Dr. Reddy's Laboratories has launched Valsartan Tablets, a generic version of Diovan® approved by the U.S. FDA. The brand had U.S. sales of approximately $150 million for the twelve months ending October 2021 according to IQVIA Health. The Valsartan Tablets are available in various dosages, including 40 mg, 80 mg, 160 mg, and 320 mg. A warning regarding fetal toxicity is included, advising discontinuation if pregnancy is detected. This launch positions Dr. Reddy’s strategically within the generic pharmaceutical market.
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) has partnered with Prestige BioPharma Ltd. to exclusively supply and commercialize Prestige's trastuzumab biosimilar in select Latin American and Southeast Asian countries. This biosimilar, HD201, is intended for treating HER2 positive breast and metastatic gastric cancer. Prestige will manage production from South Korea, while Dr. Reddy’s handles marketing and local registrations. Both companies aim to enhance access to affordable oncology treatments in these emerging markets.
FAQ
What is the current stock price of Dr Reddys Labs (RDY)?
What is the market cap of Dr Reddys Labs (RDY)?
What does Dr. Reddy's Laboratories Limited specialize in?
Where is Dr. Reddy's Laboratories headquartered?
Who founded Dr. Reddy's Laboratories?
What percentage of Dr. Reddy's generics sales come from North America?
In which therapeutic areas has Dr. Reddy's established a strong presence in India?
How many active pharmaceutical ingredients (APIs) does Dr. Reddy's manufacture?
How many countries does Dr. Reddy's distribute its APIs to?
What significance do injectables have in Dr. Reddy's North America sales?
What recent achievements has Dr. Reddy's Laboratories made?
How can investors stay updated on Dr. Reddy's latest developments?
